Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease GlobeNewswire - Mon Feb 23, 7:00AM CST

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE...

FBIO : 3.10 (+1.31%)
ATXI : 0.2673 (+8.66%)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics GlobeNewswire - Thu Nov 6, 2025

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 3.10 (+1.31%)
ATXI : 0.2673 (+8.66%)
AXSM : 164.08 (+0.02%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy GlobeNewswire - Thu Nov 6, 2025

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 201.53 (-0.11%)
ATXI : 0.2673 (+8.66%)
AXSM : 164.08 (+0.02%)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Developments Quiver Quantitative, Inc. - Fri Nov 15, 2024

Avenue Therapeutics reports third-quarter results, highlighting progress on drug development for neurologic diseases and financial challenges.Quiver AI SummaryAvenue Therapeutics, Inc. announced its third-quarter...

ATXI : 0.2673 (+8.66%)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights GlobeNewswire - Thu Nov 14, 2024

ATXI : 0.2673 (+8.66%)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit GlobeNewswire - Wed Oct 9, 2024

FBIO : 3.10 (+1.31%)
ATXI : 0.2673 (+8.66%)
Wall Street - NYSE Full View
S&P Futures Climb as Investors Weigh Economic Outlook, U.S. Bank Earnings on Tap Barchart - Tue Apr 18, 2023

June S&P 500 futures (ESM23) are trending up +0.34% this morning after three major U.S. benchmark indices ended the regular session higher as market participants digested the latest batch of corporate...

NFLX : 98.66 (+0.98%)
GOOGL : 303.13 (-0.15%)
NVDA : 183.04 (+1.66%)
CVS : 80.57 (+0.10%)
BAC : 50.30 (+0.66%)
TYL : 368.16 (+0.26%)
JNJ : 245.30 (-0.59%)
ENVX : 5.11 (+0.79%)
GS : 867.25 (+0.54%)
TD : 98.73 (+1.03%)
STT : 126.54 (+0.50%)
LMT : 664.48 (-0.50%)
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease PR Newswire - Fri Mar 10, 2023

/PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the...

ATXI : 0.2673 (+8.66%)
Wall Street - shutterstock_2763938
Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms Barchart - Fri Oct 7, 2022

December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from...

DKNG : 25.43 (+4.01%)
NVDA : 183.04 (+1.66%)
APRN : 12.99 (-0.08%)
AMD : 202.07 (+5.82%)
ATXI : 0.2673 (+8.66%)
ESZ22 : 3,871.47s (-0.66%)
LEVI : 20.81 (+0.19%)
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) ACCESS Newswire - Wed Dec 15, 2021

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics...

ATXI : 0.2673 (+8.66%)

Barchart Exclusives

Evercore ISI Says This 1 Dividend Stock Could Be a Winner Amid the Software Apocalypse Barchart - Wed Mar 4, 6:30PM CST
Evercore ISI sees C.H. Robinson as a rare AI-era winner because its agentic supply chain platform is already turning 30‑plus AI agents loose on real freight tasks, helping it gain share, expand margins, and extend a 28‑year dividend growth streak. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot